Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

checkorphan
Learn more about:
Patent ductus arteriosus
Related Clinical Trial
Clinical Profile of Neonates Having Patent Ductus Arteriosus Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Official Title

Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Brief Summary

      The investigators will conduct a prospective, blinded, randomized, placebo-controlled trial
      with a sample size of 20 patients in each of the two arms (fenoldopam vs placebo) based upon
      a difference in serum creatinine by one standard deviation. Fluid and salt intake will be
      held constant within clinical parameters and carefully measured. Fenoldopam will be started
      at 0.1 ug/kg/min. If, after 6 hrs there is no decrease in blood pressure, the dose will be
      increased to 0.2 ug/kg/min. This dose will be continued throughout the remainder of the
      study. A study of pediatric patients previously provided to the FDA showed no hypotension at
      a dose of 0.2 ug/kg/min. Fenoldopam will be started 12 hrs before the first dose of
      indomethacin and discontinued 12 hrs after the 3rd dose of indomethacin. Study samples will
      include both blood and urine. The primary outcome will be a reduction in renal dysfunction,
      as determined by creatinine and urine output over the course of treatment. Additional
      outcomes will include determination of known and novel metabolomic urine markers of renal
      dysfunction.

Detailed Description

      Hypotheses

        -  The investigators primary hypothesis is that fenoldopam reduces renal dysfunction
           associated with indomethacin administration for closure of patent ductus arteriosus in
           preterm infants. A secondary endpoint or measured outcome will be the determination of
           fenoldopam pharmacokinetics in the premature population. Lastly, the investigators
           hypothesize that urine and serum acute kidney injury (AKI) biomarkers will be superior
           to contemporary neonatal AKI definitions in their ability to identify renal injury.

      Specific Aims

        -  Evaluate the effect of fenoldopam on renal function in preterm infants administered
           indomethacin

        -  Determination of fenoldopam pharmacokinetic and pharmacodynamic profiles in preterm
           infants

        -  Define whether newly identified biomarkers of renal dysfunction are more sensitive
           markers of renal dysfunction following indomethacin than traditional markers including
           urine output and serum creatinine.

      Study design

        -  The study will be a prospective, blinded, randomized, placebo controlled trial.
           Fenoldopam will be started at 0.1 ug/kg/min. If, after 6 hrs there is no decrease in
           blood pressure, the dose will be increased to 0.2 ug/kg/min and continued throughout the
           remainder of the study. The previous study in pediatric patients showed no hypotension
           at a dose of 0.2 ug/kg/min. Fenoldopam will be started 12 hrs before the first dose of
           indomethacin and discontinued 12 hrs after the 3rd dose of indomethacin.

      Describe study population or sample material

        -  preterm infants born at less than or equal to 28 weeks gestation with patent ductus
           arteriosus in whom attempted medical closure with indomethacin is indicated as decided
           upon by the attending physician Sample size/power of primary endpoint

        -  Sample size is 20 patients in each of the two arms (fenoldopam vs placebo) based upon an
           improvement in serum creatinine by one standard deviation.

Study Phase

Phase 2/Phase 3

Study Type

Interventional

Primary Outcome

Changes in urine output (ml/kg/hr)

Condition

Patent Ductus Arteriosus (PDA)

Intervention

Fenoldopam

Study Arms / Comparison Groups

 Control
Description:  Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

40

Start Date

February 6, 2019

Completion Date

December 2022

Primary Completion Date

May 2021

Eligibility Criteria

        Inclusion Criteria:

          1. Gestational age at birth 23 0/7 to 27 6/7 weeks by best obstetrical dating

          2. No previous exposure to indomethacin

          3. Clinical determination to use indomethacin to attempt closure of PDA

          4. No known congenital abnormalities involving the kidneys, heart or lungs

          5. No preexisting renal dysfunction, defined as serum creatinine > 1.0 mg/dl, or urine
             output <1.0 ml/kg/hour over the previous 24 hours.

        Exclusion Criteria:

          1. Enrollment in concurrent study in which interventions may contribute confounding
             variables or have competing outcomes

          2. Infants with antenatally or postnatally diagnosed renal or urinary tract abnormalities

          3. Infants with umbilical cord or infant blood pH below 7.0 at any time before enrollment

          4. Attending physician unwilling to have infant participate in study

          5. Absence of informed consent

Gender

All

Ages

N/A - 28 Days

Accepts Healthy Volunteers

No

Contacts

Jeffrey Segar, MD, 319.356.7244, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT02620761

Organization ID

DK113073-01A1

Responsible Party

Principal Investigator

Study Sponsor

Medical College of Wisconsin

Study Sponsor

Jeffrey Segar, MD, Principal Investigator, University of Iowa

Verification Date

February 2021